Clinical Competition Candidate

AIRSUPRA

Respiratory · Asthma rescue (albuterol / budesonide combination inhaler)

AIRSUPRA carries use-code patent, low complexity (1/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 47 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

47months

to latest listed patent expiry (May 28, 2030)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (none)

Use-code patent (listed)

Patent count: 1

Complexity score: 1/5

Clinical competition

Score: 4/5

Active trials linked: 92

Phase 2/3 trials: 39

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: ALBUTEROL SULFATE; BUDESONIDE

Applicant (NDA holder): ASTRAZENECA PHARMACEUTICALS LP

Confidence: High

Market context

Therapeutic area: Respiratory

Indication: Asthma rescue (albuterol / budesonide combination inhaler)

U.S. market size (est.)$100M – $500M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.